Sebastian Gührs
Head of Investment @ Aescuvest
Sebastian Gührs is a Series A investor at Aescuvest focused on Health Care and Medical Device. Sebastian Guhrs is the Head of Investment at aescuvest. Sebastian Guhrs attended at CAIA Association.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 75%
Last updated:
For AI agents: llms.txt
Industries Sebastian Gührs invests in
Stages Sebastian Gührs invests in
Countries Sebastian Gührs invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (50%)
- Medical Device 2 (50%)
- Baby 1 (25%)
- Sensor 1 (25%)
- Medical 1 (25%)
Stage
- Series A 1 (25%)
- Series B 1 (25%)
- Funding Round 1 (25%)
Country
- Israel 1 (25%)
- Austria 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Neteera is bridging the gap between the human or analog world and the digital world by enabling seamless, continuous and contact-free monitoring of human vital signs.Neteera's micro-radar on chip and proprietary algorithms sense microscopic skin motions, even through furniture and clothing. This takes place at a very high frequency, allowingfor non-invasive, seamless and continuous monitoring of human vital signs such as heart and respiration rates, heart rate variability, inhale-exhale ratio, tidal volume and more. | $6.7M / Series B / Oct 31, 2023 | ||
| Neteera is bridging the gap between the human or analog world and the digital world by enabling seamless, continuous and contact-free monitoring of human vital signs.Neteera's micro-radar on chip and proprietary algorithms sense microscopic skin motions, even through furniture and clothing. This takes place at a very high frequency, allowingfor non-invasive, seamless and continuous monitoring of human vital signs such as heart and respiration rates, heart rate variability, inhale-exhale ratio, tidal volume and more. | $13M / Series B / Apr 12, 2023 | ||
| PIUR´s tomographic ultrasound solutions turn any standard ultrasound system into a tomographic 3D imaging device, bridging the gap between 2D ultrasound and regular tomographic imaging modalities. With any conventional 2D ultrasound transducer, high-resolution tomographic images can be generated and stored as quantifiable volumes, enabling true AIpost-processing for efficient diagnostics. Current focus is on thyroid imaging where AI algorithms allow doctors a fast and objective analysis and classification of thyroid nodules. | $5.3M / Series A / Apr 05, 2023 | ||
| PIUR´s tomographic ultrasound solutions turn any standard ultrasound system into a tomographic 3D imaging device, bridging the gap between 2D ultrasound and regular tomographic imaging modalities. With any conventional 2D ultrasound transducer, high-resolution tomographic images can be generated and stored as quantifiable volumes, enabling true AIpost-processing for efficient diagnostics. Current focus is on thyroid imaging where AI algorithms allow doctors a fast and objective analysis and classification of thyroid nodules. | $6.6M |
Co-Investors
About Aescuvest
Aescuvest’s mission is to facilitate and enable impactful investments into medical breakthrough innovation to disrupt and improve healthcare delivery models, products, and services. Aescuvest enables its investors to build their very individual portfolio of healthcare start-ups - according to their personal investment focus. A cooperation with EITHealth, and a growing network of partnerships across Europe, allow Aescuvest to source and evaluate the most promising healthcare investment opportunities, structure their financing rounds, and enable healthcare technology-driven investors, such as Business Angels, HNWIs, Family Offices, and Corporate Investors, to participate in healthcare investment opportunities by direct investments via SPV structures. The Investment Committee, composed of Aescuvest’s very own investment team and members of tthe Advisory Board of Aescuvest, both deeply rooted in the healthcare industry and with proven track records, have developed a strong and over the last years well tested, pre-screening and due diligence process, to identify and select healthcare start-ups. Aescuvest’’s Management (circle of General Partners) put their ‘skin’ into each investment by committing capital to each company prior introduction to the wider Aescuvest investor base. The combination of innovative ways for equity capital provision, with healthcare industry and investment expertise, provides the Aescuvest portfolio companies a unique platform to develop their business solution, accelerate their path towards commercialization, and lower market access barriers.
Aescuvest Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Sebastian Gührs
Head of Investment
|
|||
Alexander Vogt
Relationship Manager
|
|||
Ayla Haddenhorst
Relationship Manager
|
|||
Christine Schmieder
Investor Relations Manager
|
|||
Christoph Bartoschek
Startup Relations Manager
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Sebastian Gührs invest in?
Sebastian Gührs invests primarily in Health Care, Medical Device and Baby startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Sebastian Gührs?
Public channels for Sebastian Gührs include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Sebastian Gührs last invest?
The most recent investment recorded for Sebastian Gührs closed in Oct 2023. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
